Breast cancer remains a leading cause of death among women worldwide. In this context, understanding the factors that influence its diagnosis, treatment, and survival is essential for improving patient outcomes. This article explores the impact of BMI on breast cancer and precision medicine.
A recent study, published in Breast Cancer Research and Treatment, The study focused on the relationship between body mass index (BMI) and breast cancer stage at diagnosis, as well as its impact on long-term survival. The findings underscore the importance of precision medicine, which tailors treatments to individual patient characteristics, such as BMI, for more effective cancer management.
The study used data from more than 159,000 women diagnosed with breast cancer between 2014 and 2019, extracted from the California Cancer Registry. These patients were classified according to their BMI into five categories: underweight (<18.5 kg/m²), normal weight (18.5-24.9 kg/m²), overweight (25-29.9 kg/m²), obesity class 1-2 (30-39.9 kg/m²), and obesity class 3 (≥40 kg/m²).
The analysis found that underweight or obese women, especially those in classes 1-2 and 3, were more likely to be diagnosed at more advanced stages of the disease, highlighting the importance of factors beyond body weight at diagnosis. This finding reinforces the need for a more comprehensive evaluation that considers not only BMI but also other metabolic and physiological conditions that can influence prognosis.
How does BMI influence breast cancer?
BMI is a widely used indicator for classifying people according to their weight in relation to their height. However, this study demonstrates that BMI alone is not sufficient to determine the risk of developing early-stage breast cancer or its impact on long-term survival.
Underweight women had a significantly higher risk of being diagnosed at advanced stages of cancer, which is often associated with a less favorable prognosis.
In contrast, those with obesity, especially those with class 1-2 obesity, were also diagnosed at later stages, but had a higher survival rate compared to other groups.
This phenomenon, known as the “obesity paradox”, poses a complex issue in oncology: obesity does not always lead to worse outcomes, but its impact on early diagnosis remains a critical challenge.
In this context, physicians must bear in mind that BMI is not the only factor affecting disease progression. While low weight may indicate a higher likelihood of malnutrition or sarcopenia (muscle wasting), which can worsen survival, obesity can lead to other metabolic risks that negatively impact prognosis, but at the same time, it can be associated with improved survival in certain cases. This highlights the need for a more nuanced approach when evaluating BMI in relation to breast cancer.
The obesity paradox in breast cancer
The concept of the “obesity paradox” is a widely debated topic in oncology. According to this study, women with class 1-2 obesity were more likely to be diagnosed with breast cancer at more advanced stages; however, they showed greater disease-specific survival. This phenomenon challenges the traditional expectation that obesity is always associated with worse cancer outcomes. Several theories exist to explain this paradox, including the possibility that women with obesity may have greater access to aggressive medical treatments or earlier diagnoses due to their greater interaction with the healthcare system.
However, this phenomenon also suggests that BMI is not a perfect indicator of a person's metabolic health. People with obesity may have a higher amount of visceral fat, which could have implications for tumor development and progression. While the study highlights the importance of understanding the relationship between BMI and breast cancer, it also makes clear that other metabolic factors, such as systemic inflammation, insulin resistance, and fat distribution, play a crucial role in breast cancer management. Precision medicine focuses precisely on these aspects, tailoring treatment to address each patient's unique characteristics.
Precision medicine: an approach beyond BMI
Precision medicine is based on tailoring treatments to each patient's individual characteristics, including not only BMI but also body composition, genetics, and other biological factors. This study highlights the need to move beyond traditional assessment factors, such as BMI, to obtain a more comprehensive and accurate diagnosis. The future of breast cancer treatment lies in the ability to identify and treat patients based on their specific physiological and genetic characteristics. In this context, genomic testing plays a crucial role.
Zogen, a leader in precision oncology, offers advanced genomic testing that can help physicians better understand each patient's genetic makeup. These tests identify genetic mutations, hereditary risks, and other factors that can influence the progression of breast cancer. This allows treatments to be personalized to address each patient's specific needs, significantly improving survival rates and quality of life. With tools like genetic sequencing, Zogen is at the forefront of precision medicine, providing physicians and patients with crucial information for making more informed treatment decisions.
What is the impact of BMI on breast cancer and precision medicine? for doctors and patients?
The impact of these findings is profound for how physicians evaluate and treat breast cancer patients. Women who are underweight or obese should be monitored more closely for additional metabolic problems, such as sarcopenia and insulin resistance, which can complicate cancer treatment. Through a more comprehensive and personalized approach, physicians can offer more precise and tailored follow-up for each patient, leading to more effective management and more positive outcomes.
Furthermore, patients in at-risk groups, whether due to being underweight or obese, can benefit from prevention and earlier detection programs, such as the genomic tests offered by Zogen. These tests can provide valuable information for physicians, helping them identify potential genetic mutations and personalize treatment options according to each patient's individual characteristics. Precision medicine, therefore, not only improves survival but also ensures more efficient treatment tailored to each patient's specific needs.
Conclusion
This study provides crucial insights into the impact of BMI on breast cancer and precision medicine, breast cancer stage, and survival. It highlights the importance of precision medicine, which enables more tailored and effective treatment for each patient based on their physical, metabolic, and genetic characteristics. Zogen, committed to innovation in healthcare and precision oncology, continues to offer advanced tools such as genomic testing to improve cancer detection and treatment. This personalized approach has the potential to transform how we approach oncology, improving patient outcomes and quality of life. Contact us.
Full article at: https://link.springer.com/article/10.1007/s10549-025-07678-7?utm_content=buffer3a41e&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
